ESTRO 36 Programme book and exhibition guide

JOINT SYMPOSIUM ESTRO-ASTRO: Cutting edge combined modality therapies (Focus on NSCLC)

SATURDAY 6 MAY 2017

08:45 - 10:00 | AUDITORIUM Chair: Y. Lievens (Belgium) Chair: S. Hahn (USA)

08:45 > The gains to be made by combined modality treatment in NSCLC: setting the scene of new possibilities Speaker: M. Stuschke (Germany) 09:03 > The use of biomarkers for individualised treatment in NSCLC Speaker: J. Belderbos (The Netherlands) 09:21 > Abscopal responses in metastatic non-small cell lung cancer (NSCLC): a phase II study of combined radiotherapy and ipilimumab Speaker: S. Formenti (USA)

SP-0010

SP-0011

SP-0012

09:39 > The use of novel technologies (e.g. protons) in NSCLC Speaker: Z. Liao (USA)

SP-0013

SYMPOSIUMWITH PROFFERED PAPERS Radiotherapy plus immunotherapy combination: rationale and results so far 08:45 - 10:00 | SCHUBERT Chair: R. Nout (The Netherlands) Co-chair: H. Geinitz (Austria) 08:45 > In situ Cancer Vaccines: Tumor destruction and immune stimulation for local and systemic tumor control. G. Adema (The Netherlands) 09:03 > The impact of tumour infiltrating lymphocytes on clinical outcome after (chemo)radiotherapy J. Galon (France) 09:21 > Radiotherapy and immunotherapy combination: paradigm changing or just hype? S.J. Dovedi (UK) 09:39 > Combined High Dose Radiation and Ipilimumab in Metastatic Melanoma, a Phase I Dose Escalation Trial. K. De Wolf, V. Kruse, L. Brochez, N. Sundahl (Belgium), M. Van Gele, R. Speeckaert, P. Ost 09:49 > Chemoradiation-induced altered profile of PD-L1 and CD8+ TILs indicated prognosis in rectal cancer Y.J. Lim (Republic of Korea), J. Koh, S. Kim, S.R. Jeon, E.K. Chie, K. Kim, G.H. Kang, S.W. Han, T.Y. Kim, S.Y. Jeong, K.J. Park, H.G. Wu

SP-0014

SP-0015

SP-0016

OC-0017

OC-0018

SCIENTIFIC PROGRAMME | Programme and Exhibition Guide

74